Ki-67 levels may help determine if staging tests are needed for low-risk breast cancer. A study looked at patients with early breast cancer and found that those with high Ki-67 levels were more likely to develop distant metastases. However, overall, staging tests may not be necessary for low-risk breast cancer patients. Only patients with high Ki-67 levels had distant metastases, while those with low Ki-67 levels did not. Additional imaging was needed for some patients with high Ki-67 levels due to suspicious findings, but false positive rates were similar between the two groups.